MCLA-158-CL01

Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors.

Ouvert à Paris depuis le : 22/10/2021
Public cible : Adult
Phase : Phase I

Description de l'essai

This is a Phase I, open-label, multi-center, multi-national, dose escalation, single agent study to determine the recommended Phase II dose (RP2D) of MCLA-158 in metastatic colorectal cancer (mCRC). The study will assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in mCRC and other advanced solid tumors.

Url of the trial

Investigateur principal

EDITH BORCOMAN

Médecin

Contacter